SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed14d ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The amended LG Chem deal increases Rhythm's fixed payment obligations but reduces royalty burden to 1%, improving long-term margin potential. The $750M term loan provides substantial liquidity but adds leverage at SOFR + 4.60%. Monitor the closing of the initial $250M draw on Nov 6 and any subsequent draws, as well as progress of bivamelagon's clinical development and regulatory milestones.

DirectionNeutral
Confidencehigh
Horizonmonths

IMCIVREE

▲ Bullish Named in this press release
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$86.44
T+0 close · Nov 2, 2026 · via day close
Latest settled
+31.83%
T+5 · $113.95 · next T+20 in 15d
Vs SPY
+32.41%
α at T+5
Latest observation
+33.83%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $86.44entry
  2. T+1 · 13d ago +28.04%α +26.39% · $110.68
  3. T+5 · 7d ago +31.83%α +32.41% · $113.95
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals amended its global license agreement with LG Chem for bivamelagon, replacing the low-to-mid-single-digit royalty with a 1% royalty and committing $350 million in additional fixed payments over four years. To fund this and its commercial/pipeline activities, Rhythm secured a $750 million term-loan facility led by KKR's HealthCare Royalty and Blackstone, with an initial $250 million draw expected on November 6, 2026.

Key Financial Metrics

Deal Value
$350.0M

Key Facts

  • Amended LG Chem agreement: fixed payments of $350M over four years ($70M within 15 business days, $100M in Sep 2027, $100M in Sep 2028, $80M in Sep 2029).
  • Royalty reduced to 1% on global net sales of Rhythm's MC4R portfolio, starting Jan 1, 2029 or first commercial sale of bivamelagon.
  • Additional milestone payment of up to $200M if annual global net sales of MC4R portfolio reach $3B.
  • Secured $750M term-loan facility led by KKR's HealthCare Royalty and Blackstone; $500M committed, $250M initial draw at closing expected Nov 6, 2026.
  • Loan bears interest at SOFR + 4.60%, five-year term, no scheduled principal amortization, no equity component.
  • Existing revenue interest financing agreement to be amended to remove debt-like covenants and default provisions.

Financial Impact

$350M in additional fixed payments to LG Chem over four years; $750M term-loan facility ($500M committed) at SOFR + 4.60%.

debtcash flowroyalty expense

Risk Factors

  • Fixed $350M payments to LG Chem increase cash outflow risk, especially if bivamelagon commercialization is delayed.
  • Term loan carries floating-rate interest (SOFR + 4.60%), exposing Rhythm to rising rate environments.
  • Bivamelagon is still investigational; clinical or regulatory setbacks could impair the value of the amended deal.
  • Milestone payments up to $200M tied to $3B annual sales threshold may be difficult to achieve.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393875

Track record

26 reports on RYTM

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026